Table 2. Pentavalent Vaccine-3 Coverage in Serosurvey Participants by Documented (Vaccination Card or EPI Record) or Undocumented (Parental Recall Only) Source of Information.
| Documented vaccination | Undocumented vaccination | ||||
|---|---|---|---|---|---|
| Total (N) | Card or EPI register record | Cards | EPI register Record | Parental recall | |
| Hintalo Wajerate pentavalent vaccine-3 coverage in toddlers 12–23 months of age | |||||
| Coverage by source of information* | 263 | 91% (217/238)p = 0.076 | 91% (149/163)p = 0.049 | 91% (68/75)p = 1 | 48% (12/25)p = 0.18 |
| Serosurvey: tetanus antitoxin ≥ 0.15 IU/ml | 263 | 95% (227/238) | 97% (158/163) | 92% (69/75) | 68% (17/25) |
| Positive predictive value | 96.3% (209/217) | 97.3% (145/149) | 94.1% (64/68) | 41.7% (5/12) | |
| Negative predictive value | 14.3% (3/21) | 7.1% (1/14) | 28.6% (2/7) | 69.2% (9/13) | |
| Arbegona pentavalent vaccine-3 coverage in toddlers 12–23 months of age | |||||
| Coverage by source of information* | 251 | 75% (91/122)p = 0.36 | 54% (13/24)p = 0.012 | 80% (78/98)p = 0.86 | 9% (12/129)p<0.0001 |
| Serosurvey: tetanus antitoxin ≥ 0.15 IU/ml | 251 | 80% (98/122) | 92% (22/24) | 78% (76/98) | 41% (53/129) |
| Positive predictive value | 80.2% (73/91) | 92.3% (12/13) | 78.2% (61/78) | 41.7% (5/12) | |
| Negative predictive value | 19.4% (6/31) | 9.1% (1/11) | 25.0% (5/20) | 68.4% (80/117) | |
| Assaieta pentavalent vaccine-3 coverage in toddlers 12–23 months of age | |||||
| Coverage by source of Information* | 215 | 68% (57/84)p = 0.064 | 68% (50/74)p = 0.035 | 70% (7/10)p = 1 | 14% (18/131)p<0.0001 |
| Serosurvey: tetanus antitoxin ≥ 0.15 IU/ml | 215 | 79% (66/84) | 80% (59/74) | 70% (7/10) | 37% (48/131) |
| Positive predictive value | 91.2% (52/57) | 94.0% (47/50) | 71.4% (5/7) | 33.3% (6/18) | |
| Negative predictive value | 48.1% (13/27) | 50% (12/24) | 33.3% (1/3) | 78.8% (89/113) | |
| Hintalo Wajerate pentavalent vaccine-3 coverage in infants 6–8 months of age | |||||
| Coverage by source of information* | 78 | 61% (43/71)p = 0.14 | 60% (35/58)p = 0.12 | 62% (8/13)p = 1 | 29% (2/7)p = 1 |
| Serosurvey: Hib PRP antibody ≥ 1.0 mcg/ml | 78 | 70% (50/71) | 73% (42/58) | 62% (8/13) | 43% (3/7) |
| Positive predictive value | 95.3% (41/43) | 97.1% (34/35) | 87.5% (7/8) | 100.0% (1/1) | |
| Negative predictive value | 35.7% (10/28) | 34.8% (8/23) | 40.0% (2/5) | 80.0% (4/5) | |
| Arbegona pentavalent vaccine-3 coverage in infants 6–8 months of age | |||||
| Coverage by source of information* | 87 | 50% (24/48)p = 1 | 41% (9/22)p = 0.73 | 58% (15/26)p = 1 | 3% (1/39)p = 0.002 |
| Serosurvey: Hib PRP antibody ≥ 1.0 mcg/ml | 87 | 52% (25/48) | 50% (11/22) | 54% (14/26) | 28% (11/39) |
| Positive predictive value | 91.7% (22/24) | 100.0% (9/9) | 86.7% (13/15) | 100.0% (1/1) | |
| Negative predictive value | 29.2% (7/24) | 30.8% (4/13) | 27.3% (3/11) | 73.7% (28/38) | |
| Assaieta pentavalent vaccine-3 coverage in infants 6–8 months of age | |||||
| Coverage by source of information* | 81 | 83% (30/36)p = 0.001 | 83% (30/36)p = 0.001 | 0 | 4% (2/45)p = 0.031 |
| Serosurvey: Hib PRP antibody ≥ 1.0 mcg/ml | 81 | 47% (17/36) | 47% (17/36) | 0 | 18% (8/45) |
| Positive predictive value | 93.3% (28/30) | 93.3% (28/30) | - | 100.0% (2/2) | |
| Negative predictive value | 83.3% (5/6) | 83.3% (5/6) | - | 86.0% (37/43) | |
* p values compare source of vaccination history to serosurvey results by McNemar’s test (exact two-sided p-value)
Positive predictive values and negative predictive values were calculated based on antibody biomarkers as the gold standard.